Floatz logo

Pelabresib

Bone Marrow Disease

Constellation PharmaceuticalsSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Bone Marrow Disease cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Tazobactam
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
Piperacillin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
Vancomycin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2B

View all 27 →

Same molecule, other indications

Pelabresib is also rated in:

cancerDormant
BB
Indicative ·
64 / 100
View asset →
neoplasmDormant
B
Indicative ·
58 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →